GMED (GLOBUS MEDICAL INC)
Insider Trading Activity
Every open-market purchase and sale reported by GMED officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | JAMES R TOBIN | Director | MIXED | — | — |
| 2026-08-19 | STEPHEN T ZARRILLI | Director | MIXED | — | — |
| 2026-07-28 | David D Davidar | Director | G | — | — |
| 2026-06-09 | David D Davidar | Director | MIXED | — | — |
| 2026-06-08 | ANN D RHOADS | Director | M | — | — |
| 2026-02-27 | Kelly Huller | EVP, GC, Corporate Secretary | MIXED | — | — |
| 2026-02-17 | Kelly Huller | EVP, GC, Corporate Secretary | MIXED | — | — |
| 2026-01-23 | Kelly Huller | EVP, GC, Corporate Secretary | A | — | — |
| 2026-01-23 | David D Davidar | Director | A | — | — |
| 2026-01-23 | Dan Wolterman | Director | A | — | — |
| 2026-01-23 | John A DeFord | Director | A | — | — |
| 2026-01-23 | STEPHEN T ZARRILLI | Director | A | — | — |
| 2026-01-23 | JAMES R TOBIN | Director | A | — | — |
| 2026-01-23 | ANN D RHOADS | Director | A | — | — |
| 2026-01-23 | Dan Lemaitre | Director | A | — | — |
| 2026-01-23 | Robert Andrew Douglas | Director | A | — | — |
| 2026-01-23 | David C Paul | Executive Chairman | A | — | — |
| 2026-01-23 | Kyle Kline | Senior Vice President, CFO | A | — | — |
| 2026-01-23 | Keith W Pfeil | President, CEO | A | — | — |
| 2026-01-23 | Leslie V Norwalk | Director | A | — | — |
| 2026-01-13 | Kyle Kline | Senior Vice President, CFO | M | — | — |
| 2026-01-12 | Leslie V Norwalk | Director | Sell | — | — |
| 2026-01-12 | Kyle Kline | Senior Vice President, CFO | MIXED | — | — |
| 2026-01-05 | David D Davidar | Director | G | — | — |
| 2025-12-16 | Leslie V Norwalk | Director | Sell | — | — |
| 2025-12-10 | David C Paul | Executive Chairman | M | — | — |
| 2025-12-03 | Kyle Kline | Senior Vice President, CFO | MIXED | — | — |
| 2025-11-28 | Kelly Huller | SVP, GC, Corporate Secretary | MIXED | — | — |
| 2025-11-13 | STEPHEN T ZARRILLI | Director | MIXED | — | — |
| 2025-11-13 | David D Davidar | Director | MIXED | — | — |
| 2025-11-10 | ANN D RHOADS | Director | Sell | — | — |
| 2025-09-16 | ANN D RHOADS | Director | Sell | — | — |
| 2025-08-27 | Kyle Kline | Senior Vice President, CFO | A | — | — |
| 2025-08-27 | Keith W Pfeil | President, CEO | A | — | — |
| 2025-03-28 | STEPHEN T ZARRILLI | Director | A | — | — |
| 2025-03-28 | Dan Wolterman | Director | A | — | — |
| 2025-03-28 | JAMES R TOBIN | Director | A | — | — |
| 2025-03-28 | Daniel T Scavilla | President, CEO | A | — | — |
| 2025-03-28 | ANN D RHOADS | Director | A | — | — |
| 2025-03-28 | Keith W Pfeil | COO, CFO | A | — | — |
| 2025-03-28 | David C Paul | Executive Chairman | A | — | — |
| 2025-03-28 | Leslie V Norwalk | Director | A | — | — |
| 2025-03-28 | Dan Lemaitre | Director | A | — | — |
| 2025-03-28 | Kelly Huller | SVP, GC, Corporate Secretary | A | — | — |
| 2025-03-28 | Robert Andrew Douglas | Director | A | — | — |
| 2025-03-28 | John A DeFord | Director | A | — | — |
| 2025-03-28 | David D Davidar | Director | A | — | — |
| 2025-03-04 | ANN D RHOADS | Director | Sell | — | — |
| 2025-01-14 | Keith W Pfeil | COO, CFO | MIXED | — | — |
| 2024-12-04 | Kelly Huller | SVP, GC, Corporate Secretary | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,643,526 | — |
| — | 10%+ Owner | 7,643,526 | — |
| — | Director | 673,642 | — |
| — | President | 137,083 | — |
| — | President, CEO | 130,000 | — |
| — | President, CEO | 121,259 | — |
| — | Executive Chairman | 60,417 | — |
| — | Director | 44,319 | — |
| — | Director | 41,159 | — |
| — | Director | 40,384 | — |
| — | EVP, International Sales | 35,217 | — |
| — | Director | 24,025 | — |
| — | EVP, GC, Corporate Secretary | 20,000 | — |
| — | Director | 15,578 | — |
| — | President, CEO | 14,167 | — |
| — | Director | 10,419 | — |
| — | Senior VP and General Counsel | 10,000 | — |
| — | Senior Vice President, CFO | 3,594 | — |
| — | Director | 2,005 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GMED quote page; the site-wide leaderboard is on the insider transactions hub.